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Background: Whether inflammatory responses to surgery are comparably activated during total intravenous
anesthesia (TIVA) and during volatile anesthesia remains unclear. We thus compared the perioperative effects of
TIVA and isoflurane anesthesia on plasma concentrations of proinflammatory and anti-inflammatory interleukins and
cell adhesion molecules.
Methods: Patients having laparoscopic cholecystectomies were randomly allocated to two groups: 44 were
assigned to TIVA and 44 to isoflurane anesthesia. IL-1β, IL-6, IL-8, IL-10, IL-13, and the cellular adhesion molecules
intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 were determined preoperatively, before
incision, and at 2 and 24 hours postoperatively. Our primary outcomes were area-under-the-curve cytokine and
adhesion molecule concentrations over 24 postoperative hours.
Results: The only statistically significant difference in area-under-the-curve concentrations was for IL-6, which was
greater in patients given isoflurane:78 (95% confidence interval (CI): 52 to 109) pg/ml versus 33 (22 to 50) pg/ml,
P= 0.006. Two hours after surgery, IL-6 was significantly greater than baseline in patients assigned to isoflurane:
47 (95% CI: 4 to 216, P<0.001) pg/ml versus 18 (95%CI: 4 to 374, P<0.001) pg/ml in the TIVA group. In contrast,
IL-10 was significantly greater in patients assigned to TIVA: 20 (95% CI: 2 to 140, P<0.001) pg/ml versus 12 (95% CI:
3 to 126, P<0.001) pg/ml. By 24 hours after surgery, concentrations were generally similar between study groups
and similar to baseline values.
Conclusion: The only biomarker whose postoperative area-under-the-curve concentrations differed significantly as
a function of anesthetic management was IL-6. Two hours after surgery, IL-6 concentrations were significantly
greater in patients given isoflurane than TIVA. However, the differences were modest and seem unlikely to prove
clinically important. Further studies are needed.
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Surgery provokes hemodynamic, metabolic, and inflam-
matory responses; it also provokes a complex immune
reaction [1] that includes activation of the interleukin
network [2]. For example, surgery and anesthesia provoke
an increase in proinflammatory interleukins and adhesion* Correspondence: dionescuati@yahoo.com
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reproduction in any medium, provided the ormolecules, and a subsequent increase in countervailing
anti-inflammatory interleukins [3-5]. The most important
proinflammatory interleukin is IL-6, while the most potent
anti-inflammatory interleukin is IL-10.
Cell adhesion molecules (CAMs) are members of
the immunoglobulin family and are regulated by the
inflammatory interleukins [6]. CAMs promote wound
healing [7,8] and can also promote tumor progression
and metastasis [9,10], either directly or by promoting
overproduction of inflammatory interleukins. The mecha-
nisms of action differ for intercellular adhesion moleculel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ICAM-1 produces its effects by promoting recruitment
and adhesion of leukocytes to the activated endothe-
lium via bonds with integrins, thus promoting migra-
tion through endothelial cells [11]; VCAM-1, produced
mainly by the endothelial cells after interleukin-
mediated stimulation, promotes adhesion of inflam-
matory cells to the vascular wall and subsequent
migration [12]. Reduced plasma ICAM-1 concentra-
tion may facilitate tumor cell movement across vessels
into surrounding tissues, thus promoting metastasis.
Some tumor cells may also use VCAM-1 to adhere to
the vascular walls and to migrate [13,14]. CAMs are
influenced by the surgery [15] and may influence out-
come after oncological surgery [14-17].
The two major approaches to general anesthesia are
volatile anesthetics such as isoflurane and intravenous
anesthesia such as propofol. General anesthesia may
impair immune function directly by affecting immuno-
competent cells such as natural killer (NK) cells and
macrophages, cytokine responses, and adhesion mole-
cules. Alternatively, anesthesia may indirectly influ-
ence the stress response to surgery [1,5,18,19].
There appear to be substantial differences between intra-
venous and volatile anesthetics in their effects on various
immune functions [20-22]. While isoflurane inhibits inter-
feron stimulation of NK cell cytotoxicity and sevoflurane
alters the release of cytokines by NK, propofol does not
significantly suppress NK cell activity [19]. Propofol alone
increased apoptosis and cell adhesion and did not signifi-
cantly influenced cell migration in breast cancer cells,
while propofol conjugates significantly increased apoptosis
and decreased migration and adhesion in breast cancer
cells [23]. Propofol down-regulates proinflammatory inter-
leukins [24,25]. Although some studies suggest that total
intravenous anesthesia (TIVA) suppresses inflammatory
responses and promotes release of anti-inflammatory cyto-
kines [18,20,21], the reported results are inconsistent [26].
The few studies that evaluated the effects of anesthesia on
cellular adhesion molecules report that both inhalation
agents and propofol blunt the increase in ICAM and
VCAM expression [27,28]. Whether interleukins and
other inflammatory molecules are comparably activated
during TIVA and volatile anesthesia thus remains unclear.
Our study was designed to compare the effects of TIVA
and volatile anesthesia on plasma concentrations of
proinflammatory and anti-inflammatory interleukins and
on CAMs during laparoscopic surgery. Specifically, we
tested the hypothesis that TIVA blunts the inflammatory
response to laparoscopic cholecystectomy more than
isoflurane anesthesia. Laparoscopic surgery was chosen
because the amount of tissue injury is small and
similar from case to case, thus reducing the impact
of surgery per se on immune responses.Methods
After obtaining university Ethics Committee approval
(Comisia de Etica a Universitatii de Medicina si Famacie
‘Iuliu Hatieganu’, Cluj-Napoca, No. 178A/2007) and
written informed consent, we enrolled 88 patients with
American Society of Anesthesiologists physical status
scores 1 or 2 who were scheduled for laparoscopic
cholecystectomy. We excluded patients with known
inflammatory diseases (including acute cholecystitis) or
immune system disorders, asthma, obesity (body mass
index ≥30 kg/m2), diabetes, gastric ulcers, and allergies.
We also excluded patients who currently or recently
used steroid or anti-inflammatory medication, or who
had white blood cell counts >104/μl or a preoperative
core temperature >37°C.
Protocol
Midazolam, 7.5 mg orally, was given 1 hour before
surgery. Dexamethasone, 4 mg intravenously, was given
shortly before induction of anesthesia as prophylaxis
against postoperative nausea and vomiting [29]. Then
500 ml crystalloid was infused during anesthetic induc-
tion, and thereafter as clinically indicated.
Patients were randomized into two study groups using
a computer-generated sequence: one-half were assigned
to target-controlled infusion TIVA with propofol, and
one-half to isoflurane volatile anesthesia. Allocation was
concealed in sequentially numbered sealed envelopes,
with assignments revealed when patients were arriving
in the operating theater. Laboratory staff were blinded to
group assignments and anesthetic management.
TIVA was induced and maintained with a target-
controlled infusion of propofol with an initial target
plasma concentration of 4 μg/ml (Orchestra, Base
Primea; Fresenius Kabi, Fresenius Vial SAS, Brézins,
France). The propofol infusion was adjusted to target
a Bispectral Index between 40 and 55 (Covidien,
Dublin, Ireland). Isoflurane anesthesia was induced
with propofol 1.5 to 2 mg/kg and maintained with
isoflurane 1 to 1.5 minimum alveolar concentration ti-
trated to Bispectral Index 40 to 55 and hemodynamic
parameters.
Patients were ventilated with 70% oxygen in air and a
positive end-expiratory pressure of 3 to 4 cmH2O. The
respiratory rate and inspiratory pressure were adjusted
to maintain an end-tidal carbon dioxide partial pressure
of 35 to 45 mmHg (Drager-Vamos, Lubeck, Germany).
Remifentanil was infused under manual control with an
initial dose of 0.5 μg/kg/minute in the first minute and
0.25 μg/kg/minute thereafter; the remifentanil dose was
adjusted in 0.05 to μg/kg/minute increments as clinically
necessary. Atracurium 0.6 mg/kg was initially given to
provide paralysis for intubation; subsequently, 10 mg
boluses were given as clinically needed. Hypotension
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baseline) was corrected with additional fluids and/or
ephedrine. At the end of surgery, anesthesia was
discontinued and muscle relaxation antagonized with
neostigmine and atropine.
Postoperative analgesia was provided by oral paraceta-
mol 1 g every 8 hours and intravenous meperidine 0.3 to
0.4 mg/kg upon patient request or when verbal response
pain scores exceeded 3 (on a 5-point scale with 0 = no
pain and 5 = worst pain possible). Nonsteroidal agents
(nonsteroidal anti-inflammatory drugs) were not given.
Metoclopramide,10 mg intravenously, was the initial
treatment for postoperative nausea and vomiting; 4 mg
ondansetron was added if necessary.
Measurements
Routine anesthetic monitoring was used as recommended
by the American Society of Anesthesiologists.
Venous blood (7 ml) was sampled immediately after
inserting the first peripheral cannula (T1), after intub-
ation but before incision (T2), 2 hours after emergence
(T3) and 24 hours (T4) after anesthesia. Samples were
collected and centrifuged at 2,500×g for 10 minutes at
room temperature; the resulting 3 to 4 ml plasma sam-
ples were stored at less than −20°C until assayed.
Plasma concentrations of interleukins and the CAMs
soluble ICAM-1 and soluble VCAM-1 were measured
by an ELISA technique using commercially available kits
(Quantikine; R&D Systems, Minneapolis, MN, USA) as
per the manufacturer’s instructions. Laboratory staff
were unaware of study groups and were not involved in
anesthetic management.
Detection limits for interleukins as given by the manu-
facturer were as follows: IL-1, typically <1 pg/ml; IL-6,
<0.7 pg/ml; IL-8,<1.5 pg/ml; IL-10,<3.9 pg/ml; and IL-13
,<32 pg/ml. Intra-assay and inter-assay coefficients of
variation were both <10%. The detection limits for sol-
uble VCAM-1 ranged from 0.2 to 1.3 (mean =0.6) ng/ml
and the limits for soluble ICAM-1 ranged from 0.05 to
0.25 (mean = 0.10) ng/ml, with intra-assay and inter-
assay variation coefficients both <8% (Quantikine; R&D
Systems).
Normal plasma concentrations of interleukins, as
given by the manufacturer, are: IL-1β,1 to 4 pg/ml; IL-6,
0.7 to12 pg/ml; IL-8,4to 31 pg/ml; IL-13,32 to 62 pg/ml;
and IL-10,4 to 8 pg/ml. Normal plasma concentrations
of CAMs, as given by the manufacturer, are 349 to 991
ng/ml for soluble VCAM-1 and 99 to 320 ng/ml for
soluble ICAM-1.
Statistical analysis
Sample size was estimated from a pilot study with 22
patients per group. Calculated area-under-the-curve (AUC)
values for IL-6 showed a 46 pg·hour/ml difference betweenthe two groups (standard deviation = 60 and 62, respect-
ively). Using a two-tailed α error of 0.01, we estimated that
41 patients per group would provide an 80% power.
Anticipating some inadequate samples, we enrolled 44
patients in each study group.
Chi-square tests were used to assess correlations
between dichotomous data. The distribution for continu-
ous data was evaluated using the Kolmogorov–Smirnov
test, with subsequent comparison by t test or Mann–
Whitney U test as appropriate. AUC values over 24
hours and values at each measurement time were deter-
mined in individual patients using the preoperative
concentration as the baseline; between-group AUC dif-
ferences were subsequently determined using Mann–
Whitney U tests.
Data are expressed as either mean ± standard devi-
ation or median (95% confidence interval (CI)). Post-hoc
comparisons with baseline values of biomarker concen-
trations recorded at two different postoperative time
intervals were performed using the Wilcoxon test. A
Bonferroni correction was used with a consequent
reduction of the α threshold to 0.01.
Data analyses were performed using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) and Medcalc 8.3.1.1 (MedCalc
Software, Mariakerke, Belgium) statistical packages.
Results
Ninety-one patients were enrolled in the study and were
randomized (46 to isoflurane and 45 to TIVA). Three
patients were excluded from analysis because they were
discharged within 24 hours or acute inflammation of
the gallbladder was identified intraoperatively; we thus
present data from the remaining 88 patients (44 per
group) who completed the study. Demographic data
were similar in each anesthetic group, as were anesthetic
and surgical management (Table 1).
Propofol targeted plasma concentrations in the target-
controlled infusion TIVA group averaged 2.4 ± 0.5 μg/
ml. The mean end-tidal isoflurane level in patients
assigned to volatile anesthesia was 1.1 ± 0.3%.
None of the patients became hypothermic during
operation. The mean intraoperative temperature was
36.6 ± 0.2°C.
Pre-induction plasma cytokine and adhesion molecule
concentrations were similar in the two study groups
(Table 2).
Plasma concentrations for IL-1β, IL-6, IL-8, IL-10,
IL-13, soluble ICAM-1, and soluble VCAM-1are
shown in Figures 1, 2, 3, 4, 5, 6, and 7, respectively.
The largest cytokine responses to surgery were ob-
served for IL-6 and IL-10, each with significant peak
concentrations 2 hours after surgery. IL-6 was signifi-
cantly greater in patients assigned to isoflurane: 46.4
(95% CI: 34.3 to 70.7) pg/ml versus 17.6 (95% CI: 11.9
Table 1 Demographic data of the study groups
Total intravenous anesthesia (n= 44) Isoflurane (n= 44) P value
Age (years) 52 ±12 46 ±14 0.19
Weight (kg) 74 ± 16 75 ± 16 0.72
Gender (female/male) 34/10 38/6 0.40
American Society of Anesthesiologists I/II 20/24 25/19 0.39
Anesthesia time (minutes) 54 ± 15 54 ± 14 0.90
Intraoperative Bispectral Index 43 ± 4 44 ± 4 0.22
Intraoperative mean arterial pressure (mmHg) 84 ± 17 78 ± 16 0.07
Intraoperative heart rate (beats/minute) 76 ± 14 74 ± 14 0.44
Intraoperative core temperature (°C) 36.5 ± 0.3 36.6 ± 0.3 0.13
Intraoperative intravenous fluids (l) 1.2 ± 0.2 1.3 ± 0.2 0.47
Intraoperative remifentanil (μg/kg/minute) 0.3 ± 0.06 0.3 ± 0.05 1.00
Data expressed as mean ± standard deviation or number of patients.
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in patients assigned to TIVA: 20.1 (95% CI:14.2 to
32.4) pg/ml versus 12.4 (95%CI:8.8 to 18.7) pg/ml
(P = 0.03). By 24 hours after surgery, concentrations
were similar in each group and similar to baseline
values, except for IL-6 that remained significantly in-
creased in both groups (P<0.001) and for IL-10 that
remained significantly increased in patients given
isoflurane (P= 0.009). IL-4 concentrations were below
the detection limits of our assay at all times and are
therefore not reported.
Between-group comparisons of the cytokine plasma
concentration AUC for every measured parameter in the
study groups are showed in Table 3; the only significant
difference was for IL-6 (P = 0.006), with values being
greater in patients assigned to isoflurane anesthesia.
Discussion
The possibility that anesthetic management influences
long-term outcomes in surgical patients is intriguing,





Il-1β (pg/ml) 1.0 (1.02 to 1.18) 1.0 (0.99 to 1.31)
IL-6 (pg/ml) 3.4 ( 2.6 to 5.5) 2.2 (1.2 to 2.7)
IL-8 (pg/ml) 19.3 (12.4 to 34.6) 16.7 (12.1 to 24.0)
IL-10 (pg/ml) 6.1 (5.1 to 6.9) 4.8 (4.1 to 6.0)
IL-13 (pg/ml) 30.6 (27.2 to 34.0) 33.7 (28.8 to 35.8)
Soluble ICAM-1
(ng/ml)
69.0 (65.2 to 76.6) 66.1 (60.74 to 74.7)
Soluble VCAM-1
(ng/ml)
383 (349.03 to 408) 362 (335 to 402)
Data expressed as median (95% confidence interval). ICAM, intracellular
adhesion molecule; VCAM, vascular cell adhesion molecule.limited (and often controversial) evidence – or at least
plausible mechanisms – to suggest that anesthetic
management might influence diverse outcomes includ-
ing wound infection [30-32], major cardiac complica-
tions and strokes [33], brain development [34], cancer
recurrence [35-37], and mortality [30,38]. Because the
inflammatory response to surgery seems likely to be an
important potential mechanism, and possibly even a
common pathway for many outcomes, we evaluated
the cytokine responses in patients randomly assigned
to TIVA or volatile anesthesia.
Based on our primary AUC analysis, the only cytokine
that differed significantly as a function of anesthetic ap-
proach was IL-6, and the increase was only marginally
statistically significant (P= 0.006 with an α threshold of
0.01 because of multiple comparisons). Furthermore, the
factor of two increase – which is small by the standards
of cytokines – seems unlikely to be clinically important.
Judging by cytokine responses, our results thus suggest
that the choice of TIVA versus volatile anesthesia only
slightly alters the inflammatory response to surgery.
Within-group comparisons showed that IL-6 increased
significantly at 2 hours postoperatively in both groups,
but that the increase was significantly greater in patients
assigned to isoflurane anesthesia. IL-10 was also signifi-
cantly increased in both groups after 2 postoperative
hours, but with greater plasma concentrations in pa-
tients given TIVA [3]. At 24 hours postoperatively, IL-6
remained increased in both study groups while IL-10
remained increased only in the inhalation group, prob-
ably to counteract the increase in IL-6; however, the
increases were marginal.
Our results are generally consistent with previous re-
ports by Ke and colleagues, Gililand and colleagues, and
Crozier and colleagues [20-22]. For example, Ke and col-
leagues reported similar responses for IL-6 and IL-10
during laparoscopic cholecystectomy. Results reported
Figure 1 Plasma IL-1β concentrations. Data expressed as median
(95% confidence interval). T1 = before induction; T2 = immediately
after induction; T3 = at 2 hours after skin closure; T4 = at 24 hours
after skin closure. Area under the curve: isoflurane (ISO) = 3.3,
total intravenous anesthesia (TIVA) = 3.4.P= 0.428.
Figure 3 Plasma IL-8 concentrations. Data expressed as median
(95% confidence interval). T1 = before induction; T2 = immediately
after induction; T3 = at 2 hours after skin closure; T4 = at 24 hours
after skin closure. Area-under-the- curve: isoflurane (ISO) = 54,
total intravenous anesthesia (TIVA) = 49. P = 0.285.
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Crozier and colleagues after abdominal hysterectomy
were also generally similar. In contrast, Helmy and
colleagues reported that IL-6 does not increase after
laparoscopic cholecystectomy [39]. Potential explana-
tions include use of a different kit for interleukin assays
and variations in surgical technique.
Although there were differences in anesthetic protocols
and type of surgery, Deegan and coworkers observed IL-10,
IL-8, and IL-13 responses similar to ours when propofol
and paravertebral anesthesia was compared with volatileFigure 2 Plasma IL-6 concentrations. Data expressed as median
(95% confidence interval).T1 = before induction; T2 = immediately
after induction; T3 = at 2 hours after skin closure; T4 = at 24 hours
after skin closure. Area-under-the-curve: isoflurane (ISO) = 78,
total intravenous anesthesia (TIVA)= 33. P = 0.006.anesthesia [35]. However, they also found that IL-6 concen-
trations did not much differ as a function of anesthetic
dose. Potential explanations include their use of regional
anesthesia rather than TIVA, breast surgery rather than
abdominal surgery, and the fact that all their patients had
cancer, which per se can depress immune responses.
Furthermore, in our study neither soluble ICAM-1 nor
soluble VCAM-1 differed significantly as an effect of
anesthetic technique.
A possible explanation for the results on interleukins
may consist of the antioxidants and anti-inflammatoryFigure 4 Plasma IL-10 concentrations. Data expressed as median
(95% confidence interval). T1 = before induction; T2 = immediately
after induction; T3 = at 2 hours after skin closure; T4 = at 24 hours
after skin closure. Area-under-the-curve: isoflurane (ISO) = 26,
total intravenous anesthesia (TIVA) = 37. P = 0.151.
Figure 5 Plasma IL-13 concentrations. Data expressed as median
(95% confidence interval). T1 = before induction; T2 = immediately
after induction; T3 = at 2 hours after skin closure; T4 = at 24 hours
after skin closure. Area-underthe- curve: isoflurane (ISO) = 101,
total intravenous anesthesia (TIVA) = 93. P = 0.218.
Figure 7 Plasma solublevascular cell adhesion molecule-1
concentrations. Data expressed as median (95% confidence
interval). T1 = before induction; T2 = immediately after induction;
T3 = at 2 hours after skin closure; T4 = at 24 hours after skin closure.
Area-under –the-curve: isoflurane (ISO) = 1029, total intravenous
anesthesia (TIVA) = 1139. P = 0.226. VCAM, vascular cell
adhesion molecule.
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effects of inhalation agents [41]. As for adhesion mole-
cules, our results with inhalation anesthesia are similar
to other studies [42], confirming that isoflurane has an
inhibitory effect on CAMs. Moreover, we have demon-
strated that there are no differences between inhalation
anesthesia and TIVA. The anti-inflammatory effects of
propofol may thus involve mechanisms other than
adhesion molecules.
Directly comparing our results with previous publica-
tions is difficult since each study evaluated differentFigure 6 Plasma soluble intercellular adhesion molecule-1
concentrations. Data expressed as median (95% confidence
interval). T1 = before induction; T2 = immediately after induction;
T3 = at 2 hours after skin closure; T4 = at 24 hours after skin closure.
Area-under-the-curve: isoflurane (ISO)= 197, total intravenous
anesthesia (TIVA)= 213. P = 0.488. ICAM, intracellular
adhesion molecule.anesthetic protocols, different surgical interventions, and
used different cytokine assays. Nonetheless, our results
are thus generally consistent with the previous literature
and are among the largest that evaluated a single typical
operation.
Our study does have some limitations. A low dose of
dexamethasone (4 mg) was given to all patients for
prophylaxis against postoperative nausea and vomiting,
as is common in clinical practice. It is wellknown that
steroids are immunosuppressive and may have amelio-
rated the inflammatory response to surgery. Observed
differences between the randomized TIVA and volatile




Isoflurane (n= 44) Pvalue
IL-1β (pg·hour/ml) 3.4 (3.0 to 4.3) 3.3 (2.9 to 4.0) 0.428
IL-6 (pg·hour/ml) 33.0 (21.6 to 44.9) 78.0 (52.2 to 109.1) 0.006
IL-8 (pg·hour/ml) 49.0 (39.6 to 67.0) 54.0(47.2 to 82.6) 0.285
IL-10 (pg·hour/ml) 37.0 (23.8 to 55.4) 26.0 (21.6 to 42.1) 0.151
IL-13 (pg·hour/ml) 93.0 (83.4 to 101.3) 101.0 (89.8 to 112.1) 0.218
Soluble ICAM-1
(ng·hour/ml)
213 (188.0 to 242.3) 197 (178.9 to 220.9) 0.488
Soluble VCAM-1
(ng·hour/ml)
1,139 (1,029 to 1,188) 1,029 (947 to 1,163) 0.226
Data expressed as median (95% confidence interval). Area-under-the-curve
based on preoperative values. Mann–Whitney U tests were used for between-
group comparisons; because multiple comparisons were made, P<0.01 was
considered statistically significant. Bold data are significant.
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in patients not given steroids. A more serious consider-
ation is that laparoscopic cholecystectomies produce
only a moderate amount of tissue injury, and cholecyst-
ectomies presumably provoke a smaller inflammatory
response than larger operations. They nonetheless well
represent the types of surgery that are most commonly
performed. On the contrary, having only a minor inflam-
matory response due to surgery, the differences may be
more attributable to anesthetic technique.
Immune response is a mosaic in which interleukins and
adhesion molecules are but one piece. However, it is an
important piece because exaggerated or abnormally low
cytokine concentrations may have a substantial effect on
patient outcome. For example abnormally increased levels
of IL-6 are involved in systemic inflammatory response
with impact on outcome and postoperative complications,
and even on prognosis and mortality in cancer patients
[43,44]. However, we observed relatively small differences
between isoflurane anesthesia and TIVA, and only over a
short period of time; whether this difference is clinically
important remains unknown — but seems somewhat
unlikely.
In summary, IL-6 and IL-10 increased significantly 2
hours after incision. There were no other statistically sig-
nificant or clinically important perioperative increases.
The only significant difference in cytokine concentra-
tions related to anesthetic management was a greater in-
crease in the IL-6 AUC with isoflurane anesthesia than
with TIVA. However, the increase was only a factor-of
-two, which is small by cytokine standards. The AUC
concentrations were greater for IL-10 (P= 0.15), soluble
ICAM-1 (P = 0.49), and soluble VCAM-1 (P = 0.23) in
patients assigned to TIVA, although not significantly.Conclusion
TIVA significantly reduced the increase in IL-6 during
the perioperative period as compared with isoflurane.
IL-10 and the adhesion molecules were increased,
although not significantly. This effect may be favorable
in some patients (for example, increased systemic
inflammatory response). Further studies on larger groups
of patients and for more extensive surgical interventions
are needed for a better evaluation of the extent of this
effect and its clinical impact.Abbreviations
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